Skip to content

COVID-19 pilot study from Münster was published

No quod sanctus instructior ius, et intellegam interesset duo. Vix cu nibh gubergren dissentias. His velit veniam habemus ne. No doctus neglegentur vituperatoribus est, qui ad ipsum oratio. Ei duo dicant facilisi, qui at harum democritum consetetur.

A COVID-19 pilot study from Münster (60 patients) about the significance of previous infections with OC43 viruses on COVID-19 disease progression was published in the International Journal of Infectious Diseases (for more information click here).

By measuring OC43-NP antibodies it is possible to better identify individuals at increased risk for severe COVID-19 disease progression. This issue is clinically relevant with respect to the use of new, limited therapies for COVID-19 patients (identification of patients at risk) and for the prioritization of vaccinations.

Within the framework of the HiGHmed Use Case Infection Control the clinical data from Münster were provided by their MeDIC (Medical Data Integration Center).

The idea for this work arose in the context of the Coronaplasma study of the Med B in Münster. During a survey of the plasma donors it was noticed that many persons with a mild COVID-19 disease progression had contact with children under 10 years of age (conspicuously high proportion of persons who work in a kindergarten or in elementary school or have young children of their own. This is how the hypothesis came about that childhood-related infection has a protective effect against COVID-19. The results of this survey were published last year, also in the International Journal of Infectious Diseases (for more information click here).

The results of the study that was just accepted for publication could be validated in a multicenter validation study with almost 300 patients. The manuscript of this validation study is currently under review (preprint). For more information click here.

Leave a Comment